Your session is about to expire
← Back to Search
ABSK121-NX for Solid Tumors
Study Summary
This trial studies the safety and effectiveness of a new drug to treat advanced solid tumors. It will look at the best dose to use and how it affects tumors.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am scheduled for a major surgery during the study.My phosphate levels have been high despite treatment.I cannot swallow pills or have a condition affecting my stomach or intestines.I am 18 years old or older.My side effects from previous cancer treatments are mild or gone.I haven't had cancer treatment like chemo or targeted therapy recently.I have previously been treated with FGFR inhibitors.My cancer has spread to my brain.I have not received a live vaccine recently.I have fluid buildup that is not responding to treatment.My organs and bone marrow are working well, as shown by recent tests.I have AIDS or tested positive for HIV.I do not have heart problems or diseases.I have been treated with FGFR inhibitors for my solid tumor.I have an advanced solid tumor.I have not taken FGFR inhibitors before for my cancer.I have UC or iCCA and my condition worsened after FGFR inhibitor treatment.I have another cancer that is getting worse or needs treatment.My advanced cancer has not responded to, or I cannot tolerate, standard treatments.I am fully active or can carry out light work.I have not had major surgery in the last 4 weeks.I haven't taken strong CYP3A4 drugs recently.My cancer has FGFR genetic changes confirmed by tests.
- Group 1: ABSK121-NX
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the primary objective of this research endeavor?
"The primary measure of this trial, assessed across a 28 day period, is the incidence and severity of adverse events. Secondary outcomes include duration of response (DoR), progression-free survival (PFS) as well as accumulation ratio (AR)."
Has this experiment spread to multiple sites in the US?
"At present, the trial is running in 7 different cities - FuZhou, Haerbin and Shenyang as well as 4 additional locales. To reduce travel demands, it's best to choose a centre nearby when signing up for this research endeavour."
Has the administration sanctioned ABSK121-NX for public use?
"The safety of ABSK121-NX, which is still in its first round of clinical trials, has been preliminarily assessed as a 1. This represents that the medication's efficacy and security are both relatively untested."
Are there any current openings for this clinical research?
"Yes, the details available on clinicaltrials.gov confirm that this medical trial is presently recruiting participants. It was initially posted in June of 2023 and has since been updated; it seeks to enroll 169 patients across 7 sites."
How many participants will be surveyed in this research endeavor?
"Indeed. Records on clinicaltrials.gov corroborate that this experimental trial, which was initially posted on June 26th 2023, is actively searching for participants. 169 individuals are required from 7 distinct sites to complete the study."
Share this study with friends
Copy Link
Messenger